文献速递分子诊断质量管理与危急值

基孔肯雅病毒核酸检测质控国家参考品体系的开发与验证

Development and validation of a national reference material system for quality control of chikungunya virus nucleic acid detection assays.
PubMed 文献 · J Clin Microbiol · 2026-05-06

针对WHO缺乏基孔肯雅病毒核酸国际标准品的问题,本研究使用完整灭活病毒颗粒开发了包含定量标准品和验证盘的国家参考品体系。标准品经8个dPCR平台多实验室定值,浓度为7.60 ± 0.14 log10 copies/mL(k=2);9种试剂盒评估显示阳性和阴性样本100%一致,重复性CV<5%,声称检测限下阳性率≥95%。

要点

  • 标准品定值为7.60 ± 0.14 log10 copies/mL(k=2),量值可溯源。
  • 9种试剂盒检测阳性和阴性样本均达100%一致。
  • 重复性CV<5%,声称检测限下各试剂盒阳性率≥95%。

核心结论

  • 成功开发并验证了基于完整灭活病毒颗粒的基孔肯雅病毒核酸检测国家参考品体系,可支持检测标准化、开发和质量控制。

研究设计与样本

  • 使用完整灭活基孔肯雅病毒颗粒制备定量标准品和验证盘,覆盖亚洲型和东/中/南非型基因型。
  • 标准品通过8个数字PCR平台的多实验室研究定值。
  • 使用9种试剂盒进行广泛评估。

主要发现

  • 标准品定值浓度为7.60 ± 0.14 log10 copies/mL(k=2)。
  • 9种试剂盒检测阳性和阴性样本均显示100%一致。
  • 重复性变异系数CV<5%,声称检测限下所有试剂盒阳性率≥95%。

临床怎么用

  • 可用于监管审评、制造商质量控制和实验室间比对,统一检测性能。
  • 有助于降低因病毒遗传多样性导致的假阴性风险。
  • 可促进检测方法优化并提高监测数据一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The absence of a World Health Organization (WHO) international standard for Chikungunya virus (CHIKV) nucleic acid testing has long impeded the comparability of diagnostic results across different assays and platforms. To address this critical gap in quality assurance, we developed and rigorously characterized a national reference material system consisting of a quantified standard and a validation panel for CHIKV molecular detection. These materials were developed using intact, inactivated CHIKV particles to closely mimic clinical extraction and amplification. The assigned value of the standard was determined through a robust multi-laboratory study using eight digital polymerase chain reaction (dPCR) platforms, yielding a traceable concentration of 7.60 ± 0.14 log10 copies/mL (k = 2). Extensive evaluation using nine kits demonstrated 100% concordance for both positive and negative samples. The materials exhibited excellent repeatability (coefficient of variation, CV <5%) and consistent detectability (≥95% positivity rate) at the claimed limit of detection across all kits. In summary, this study developed a well-characterized reference material system to support the standardization, development, and quality control of CHIKV nucleic acid assays. The availability of this reference material system addresses a longstanding limitation of results across different platforms and geographical regions. Their implementation is expected to facilitate assay optimization and improve the consistency of surveillance data, thereby strengthening preparedness and the accurate identification of cases, especially in non-endemic areas at risk of importation.IMPORTANCEThe absence of a World Health Organization (WHO) international standard for Chikungunya virus (CHIKV) nucleic acid testing has long compromised result comparability and global outbreak response. Here, we established a national reference material system derived from intact, inactivated CHIKV particles-authentically mirroring the entire clinical workflow. Covering both Asian and East/Central/South African (ECSA) genotypes, this system mitigates false-negative risks caused by viral genetic diversity. Assigned via multi-laboratory dPCR and validated across nine commercial kits, it demonstrated 100% concordance, ≥95% detectability at LoD, and coefficient of variation (CV) <5%. This traceable, genotype-inclusive, workflow-authentic benchmark enables, for the first time, unified performance alignment for regulatory review, manufacturer quality control, and inter-laboratory comparison. It fills a critical gap in domestic quality assurance while providing a technical template for future WHO standardization efforts. Widespread adoption will accelerate reliable diagnostics, strengthen surveillance comparability, and support timely clinical decisions in both endemic and importation-prone settings.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Ma T, Zhao L, Luo C, et al. Development and validation of a national reference material system for quality control of chikungunya virus nucleic acid detection assays. J Clin Microbiol. 2026. PMID: 42089621. doi:10.1128/jcm.01543-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。